Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1977 1
1983 1
1984 1
1991 1
1997 1
1998 1
1999 1
2000 1
2001 2
2002 5
2003 8
2004 17
2005 14
2006 17
2007 15
2008 10
2009 10
2010 4
2011 8
2012 3
2013 4
2014 3
2015 1
2018 1
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 15872078

123 results
Results by year
Filters applied: . Clear all
Page 1
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM. Zhang Z, et al. J Am Soc Nephrol. 2005 Jun;16(6):1775-80. doi: 10.1681/ASN.2004080632. Epub 2005 May 4. J Am Soc Nephrol. 2005. PMID: 15872078 Free article.
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group. Bakris GL, et al. Arch Intern Med. 2003 Jul 14;163(13):1555-65. doi: 10.1001/archinte.163.13.1555. Arch Intern Med. 2003. PMID: 12860578 Clinical Trial.
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Keane WF, et al. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. doi: 10.1053/ajkd.2003.50078. Am J Kidney Dis. 2003. PMID: 12612946 Review.
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S; RENAAL Study Investigators. Brenner BM, et al. J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):328-35. doi: 10.3317/jraas.2000.062. J Renin Angiotensin Aldosterone Syst. 2000. PMID: 11967819 Free article. Clinical Trial.
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B, Gleim G, Panish J. Egan B, et al. Curr Med Res Opin. 2004 Dec;20(12):1909-17. doi: 10.1185/030079904X13040. Curr Med Res Opin. 2004. PMID: 15701209 Clinical Trial.
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. de Zeeuw D, et al. Kidney Int. 2004 Jun;65(6):2309-20. doi: 10.1111/j.1523-1755.2004.00653.x. Kidney Int. 2004. PMID: 15149345 Free article. Clinical Trial.
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S. Carr AA, et al. Am J Cardiol. 2005 Dec 1;96(11):1530-6. doi: 10.1016/j.amjcard.2005.07.061. Epub 2005 Oct 17. Am J Cardiol. 2005. PMID: 16310435 Clinical Trial.
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Eijkelkamp WB, et al. J Am Soc Nephrol. 2007 May;18(5):1540-6. doi: 10.1681/ASN.2006050445. Epub 2007 Apr 4. J Am Soc Nephrol. 2007. PMID: 17409317 Free article. Clinical Trial.
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM. Tershakovec AM, et al. Diabetes Care. 2008 Mar;31(3):445-7. doi: 10.2337/dc07-0196. Epub 2007 Dec 10. Diabetes Care. 2008. PMID: 18070995
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. de Zeeuw D, et al. Circulation. 2004 Aug 24;110(8):921-7. doi: 10.1161/01.CIR.0000139860.33974.28. Epub 2004 Aug 9. Circulation. 2004. PMID: 15302780 Clinical Trial.
123 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback